Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours
Bull Cancer. 2023 Oct 6:S0007-4551(23)00348-X. doi: 10.1016/j.bulcan.2023.08.002. Online ahead of print.ABSTRACTThe landscape of uterine sarcomas is becoming more complex with the description of new entities associated with recurrent driver molecular alterations. Uterine sarcomas, in analogy with soft tissue sarcomas, are distinguished into complex genomic and simple genomic sarcomas. Leiomyosarcomas and undifferentiated uterine sarcomas belong to complex genomic sarcomas group. Low-grade and high-grade endometrial stromal sarcomas, other rare tumors associated with fusion transcripts (such as NTRK, PDGFB, ALK, RET ROS1) a...
Source: Bulletin du Cancer - October 8, 2023 Category: Cancer & Oncology Authors: Sabrina Croce Mojgan Devouassoux-Shisheboran Patricia Pautier Isabelle Ray-Coquard Isabelle Treilleux Agn ès Neuville Laurent Arnould Pierre-Alexandre Just Marie Aude Le Frere Belda Gerlinde Averous Agn ès Leroux Guillaume Bataillon Eliane Mery Delphine Source Type: research
Cancers, Vol. 15, Pages 4880: Genome-Wide DNA Methylation Profiling as Frontline Diagnostics for Central Nervous System Embryonal Tumors in Hong Kong
This study retrospectively analyzed pediatric patients with CNS embryonal tumors in Hong Kong between 1999 and 2017, using data from the territory-wide registry and available formalin-fixed paraffin-embedded tumor tissue. After processing archival tumor tissue via DNA extraction, quantification, and methylation profiling, the data were analyzed by using the web-based DKFZ classifier (Molecular Neuropathology (MNP) 2.0 v11b4) and t-SNE analysis. Methylation profiles were deemed informative in 85 samples. Epigenetic data allowed molecular subgrouping and confirmed diagnosis in 65 samples, verified histologic diagnosis in 8, ...
Source: Cancers - October 7, 2023 Category: Cancer & Oncology Authors: Otto C. H. Tam Ronnie S. L. Ho Shing Chan Kay K. W. Li Tit-Leung Lam Elaine T. Y. Cheung Oi-Yee Cheung Wilson W. S. Ho Kevin K. F. Cheng Matthew M. K. Shing Dennis T. L. Ku Brian H. Y. Chung Wanling Yang Godfrey C. F. Chan Ho-Keung Ng Anthony P. Y. Liu Tags: Article Source Type: research
Analysis of a mouse germ cell tumor model establishes pluripotency-associated miRNAs as conserved serum biomarkers for germ cell cancer detection
bioRxiv. 2023 Sep 12:2023.09.09.556995. doi: 10.1101/2023.09.09.556995. Preprint.ABSTRACTMalignant testicular germ cells tumors (TGCTs) are the most common solid cancers in young men. Current TGCT diagnostics include conventional serum protein markers, but these lack the sensitivity and specificity to serve as accurate markers across all TGCT subtypes. MicroRNAs (miRNAs) are small non-coding regulatory RNAs and informative biomarkers for several diseases. In humans, miRNAs of the miR-371-373 cluster are detectable in the serum of patients with malignant TGCTs and outperform existing serum protein markers for both initial d...
Source: Cancer Control - September 25, 2023 Category: Cancer & Oncology Authors: Amanda R Loehr Dennis M Timmerman Michelle Liu Ad J M Gillis Melia Matthews Jordana C Bloom Peter K Nicholls David C Page Andrew D Miller Leendert H J Looijenga Robert S Weiss Source Type: research
Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma
CONCLUSION: The pathogenesis of STS including FN-RMS remains poorly understood, emphasizing the need for new therapeutic advances and adequate risk stratification. Our data demonstrate that loss of chr3q is associated with poor OS in FN-RMS, supporting it as an important tool for risk stratification.PMID:37738543 | DOI:10.1200/PO.23.00037 (Source: Ann Oncol)
Source: Ann Oncol - September 22, 2023 Category: Cancer & Oncology Authors: Carina A Dehner Robert C Bell Yang Cao Kevin He John S A Chrisinger Amy E Armstrong Marielle Yohe Jack Shern Angela C Hirbe Source Type: research
Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma
CONCLUSION: The pathogenesis of STS including FN-RMS remains poorly understood, emphasizing the need for new therapeutic advances and adequate risk stratification. Our data demonstrate that loss of chr3q is associated with poor OS in FN-RMS, supporting it as an important tool for risk stratification.PMID:37738543 | DOI:10.1200/PO.23.00037 (Source: Ann Oncol)
Source: Ann Oncol - September 22, 2023 Category: Cancer & Oncology Authors: Carina A Dehner Robert C Bell Yang Cao Kevin He John S A Chrisinger Amy E Armstrong Marielle Yohe Jack Shern Angela C Hirbe Source Type: research
Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity
Cancer Res Commun. 2023 Sep 21. doi: 10.1158/2767-9764.CRC-23-0119. Online ahead of print.ABSTRACTThe tumor-specific chromosomal translocation product, PAX3::FOXO1, is an aberrant fusion protein that plays a key role for oncogenesis in the alveolar subtype of rhabdomyosarcoma (RMS). PAX3::FOXO1 represents a validated molecular target for alveolar RMS and successful inhibition of its oncogenic activity is likely to have significant clinical applications. Even though several PAX3::FOXO1 function-based screening studies have been successfully completed, a directly binding small molecule inhibitor of PAX3::FOXO1 has not been r...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Kay Nakazawa Taryn Shaw Young K Song Marilyn Kouassi-Brou Anna Molotkova Purushottam B Tiwari Hsien-Chao Chou Xinyu Wen Jun S Wei Emre Deniz Jeffrey Toretsky Charles Keller Frederic G Barr Javed Khan Aykut Üren Source Type: research
Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry
CONCLUSION: RT can be omitted in patients with IRS I eRMS. RT improves LCS and EFS in IRS II and III. RT improves OS in patients with HN-PM, with proton RT comparable with photon RT. Doses of 32 Gy (HART) or 36 and 41.4 Gy (CFRT) had comparable efficacy in patients with favorable risk profiles and 44.8 Gy (HART) or 50.4 and 55.8 Gy (CFRT) in the unfavorable groups.PMID:37725766 | DOI:10.1200/JCO.22.02673 (Source: Cancer Control)
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Ewa Koscielniak Beate Timmermann Marc M ünter Jadwiga Weclawek-Tompol Ruth Ladenstein Felix Niggli Gustaf Ljungman Ines B Brecht Bernd Blank Erika Hallmen Monika Scheer Joerg Fuchs Guido Seitz Claudia Blattmann Monika Sparber-Sauer Thomas Klingebiel Source Type: research
Adult Laryngeal Pleomorphic Rhabdomyosarcoma: A Rare Entity
Ear Nose Throat J. 2023 Sep 16:1455613231198986. doi: 10.1177/01455613231198986. Online ahead of print.ABSTRACTRhabdomyosarcoma (RMS) is a rare and aggressive cancerous tumor that arises from embryonal mesenchymal cells with skeletal muscle differentiation, and it is exceedingly rare that occurs specifically in the larynx. To date, only 22 instances of laryngeal pleomorphic RMSs have been documented in adults. Consequently, there is limited information available to assist healthcare professionals in effectively handling RMS in the larynx of adult patients. Here, we present an uncommon occurrence involving a 45-year-old man...
Source: Ear, Nose and Throat Journal - September 16, 2023 Category: ENT & OMF Authors: Hua Cai Shan Chen Zhuo-Ya Zhang Bei-Bei Gao Yan-Yan Ding Bang-Hua Liu Wen-Wen Wang Source Type: research
